Abstract
Background: Post-prandial hyperglycemia (PPHG) appears to be the rate limiting factor for achieving optimal glycemic control in Type 2 diabetes (T2D). In DECODA study, 2 h postprandial plasma glucose (PPG) was found to be superior to fasting plasma glucose (FPG) in predicting premature CV mortality. Clinical use of Repaglinide and Voglibose combination in T2D offers post-prandial glucose regulation while modulating the first phase of insulin secretion that is often blunted in such cases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
